Celcuity Inc
NASDAQ:CELC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Celcuity Inc
Research & Development
Celcuity Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celcuity Inc
NASDAQ:CELC
|
Research & Development
-$140.8m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-82%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$6.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-13%
|
|
Celcuity Inc
Glance View
Celcuity, Inc. is cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 39 full-time employees. The company went IPO on 2017-09-20. The firm is focused on discovering cancer sub-types molecular-based approaches through developing companion diagnostic tests (CDx) and therapeutic (Rx). The firm's product pipeline includes CELsignia platform and Gedatolisib. The CELsignia diagnostic platform is used to analyze live patient tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy. The CELsignia platform provides traditional molecular diagnostics, which includes snapshot of the genetic mutations present in a patients tumor because they analyze cell fragments and molecular diagnostics can estimate the patients potential drug response based on a statistical analysis of the drugs clinical trial result. Its other product candidate includes Gedatolisib, is a small molecule dual inhibitor, administered intravenously, that targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR).
See Also
What is Celcuity Inc's Research & Development?
Research & Development
-140.8m
USD
Based on the financial report for Sep 30, 2025, Celcuity Inc's Research & Development amounts to -140.8m USD.
What is Celcuity Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-82%
Over the last year, the Research & Development growth was -59%. The average annual Research & Development growth rates for Celcuity Inc have been -67% over the past three years , -82% over the past five years .